Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Galecto, Inc. (GLTO : NSDQ)

• Company Description    Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on galectin-3 and LOXL2. The Company's pipeline includes an inhaled galectin-3 modulator currently in Phase 2b for the potential treatment of idiopathic pulmonary fibrosis. Galecto Inc. is headquarters in Copenhagen, Denmark. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $23.01 Daily Weekly Monthly 20 Day Moving Average: 107,675 shares Shares Outstanding: 1.60 (millions) Market Capitalization: $36.71 (millions) Beta: 1.41 52 Week High: $38.33 52 Week Low: $2.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.93% 3.99% 12 Week 116.06% 113.16% Year To Date 394.84% 325.16%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 75 State Street Suite 100 - Boston,MA 02109 DNK ph: 45-7070-5210 fax: - svonderweid@lifesciadvisors.com http://www.galecto.com

• General Corporate Information    Officers Hans T. Schambye - President; Chief Executive Officer and Director Carl Goldfischer - Chairman Lori Firmani - Interim Chief Financial Officer Jayson Dallas - Director Amit Munshi - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 36322Q206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/18/26 Share - Related Items Shares Outstanding: 1.60 Most Recent Split Date: 8.00 (0.04:1) Beta: 1.41 Market Capitalization: $36.71 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/18/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.57 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 30.38% vs. Previous Quarter: 9.23% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -147.05 06/30/25 - -115.70 ROA 12/31/25 - - 09/30/25 - -111.33 06/30/25 - -95.42 Current Ratio 12/31/25 - - 09/30/25 - 3.73 06/30/25 - 4.96 Quick Ratio 12/31/25 - - 09/30/25 - 3.73 06/30/25 - 4.96 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 5.03 06/30/25 - 7.27 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©